Sign inCreate account

Report workspace tools

NCT02342249COMPLETEDanonymous

A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study of 2 Dose Levels of VX 787 Administered as Monotherapy and One Dose Level of VX-787 Administered in Combination With Oseltamivir for the Treatment of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Sponsor

Source record

Janssen Research & Development, LLC

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo

Indication / condition

AI-normalized

Influenza A

Intervention

Source record

VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo

Source & freshness

Source record

NCT ID

NCT02342249

Original source

ClinicalTrials.gov

Source last updated

Feb 04, 2025

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02342249

Title

A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study of 2 Dose Levels of VX 787 Administered as Monotherapy and One Dose Level of VX-787 Administered in Combination With Oseltamivir for the Treatment of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Sponsor

Janssen Research & Development, LLC

Status

COMPLETED

Phase

PHASE2

Condition raw

Influenza A

Condition normalized

Influenza A

Modality raw

small molecule

Modality normalized

small molecule

Target raw

VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo

Target normalized

VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo

Interventions

VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo

Public preview

Source record

The purpose of this study is to evaluate the antiviral effect, as measured by viral titer in nasal secretions in adults with acute uncomplicated seasonal influenza A following administration of VX-787.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study of 2 Dose Levels of VX 787 Administered as Monotherapy and One Dose Level of VX-787 Administered in Combination With Oseltamivir for the Treatment of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02342249

Status

COMPLETED

Phase

PHASE2

Sponsor

Janssen Research & Development, LLC

Executive brief

Investment-Ready Snapshot

The purpose of this study is to evaluate the antiviral effect, as measured by viral titer in nasal secretions in adults with acute uncomplicated seasonal influenza A following administration of VX-787.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedFeb 04, 2025
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02342249

Indication

Influenza A

Modality

small molecule

Target

VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo

Intervention

VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.